Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA.
Pharmacotherapy Division, The University of Texas at Austin College of Pharmacy, Austin, Texas, USA.
J Clin Psychiatry. 2020 Feb 18;81(2):TV18059AH3C. doi: 10.4088/JCP.TV18059AH3C.
The use of second-generation antipsychotics has not eliminated tardive dyskinesia (TD), and the prevalence of the disorder is higher than commonly realized. The involuntary movements of TD can decrease patients' quality of life, cause embarrassment, and lead to social withdrawal. Clinicians must evaluate patients taking DRBAs for TD risk factors and regularly screen them for TD using a rating scale. Familiarity with tools and diagnostic criteria will enable clinicians to conduct a differential diagnosis. Once a diagnosis is made, medications approved by the US Food and Drug Administration can be used to treat the condition. These medications are effective, but clinicians should be aware of key differences. A baseline assessment and regular follow-up evaluations will allow the clinician to monitor the patient's progress and make adjustments to meet treatment goals..
第二代抗精神病药物的使用并没有消除迟发性运动障碍（TD），而且这种疾病的患病率比人们通常意识到的要高。TD 的不自主运动可降低患者的生活质量，导致尴尬，并导致社会退缩。临床医生必须评估服用 DRBAs 的患者的 TD 风险因素，并使用评分量表定期对其进行 TD 筛查。熟悉工具和诊断标准将使临床医生能够进行鉴别诊断。一旦做出诊断，可以使用美国食品和药物管理局批准的药物来治疗该病症。这些药物是有效的，但临床医生应该注意关键的差异。基线评估和定期随访评估将使临床医生能够监测患者的进展情况，并进行调整以达到治疗目标。
